Kuwait Life Sciences Company
Kuwait Life Sciences Company (KLSC), established in 2010, operates as a venture capital firm based in Safat, Kuwait. It is fully owned by the National Technology Enterprises Company, which serves as the investment arm of the Kuwait Investment Authority. KLSC specializes in healthcare innovations, targeting unmet needs in the Middle East and North Africa (MENA) region. The company engages in healthcare investments, life sciences training, medical technology, and pharmaceutical distribution. KLSC employs a strategic investment approach that encompasses incubation of local and regional projects, international venture capital investments, and private equity in established companies. It partners with private sector entrepreneurs to foster technology transfer and supports projects that align with regional demands. Noteworthy initiatives developed by KLSC include the Life Sciences Academy and platforms for medical devices and pharmaceuticals. The firm focuses on pre-commercialization stage companies with substantial growth potential, as well as established healthcare firms aiming for regional expansion. By leveraging its expertise, KLSC aims to enhance healthcare services and systems within the MENA region.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
NewBridge Pharmaceuticals
Series C in 2013
NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, that focuses on pharmaceuticals, biologics, and medical diagnostics. Established in 2007, the company specializes in in-licensing and commercializing healthcare products to meet the unmet medical needs of patients in the Middle East, Africa, Turkey, and the Caspian regions. NewBridge offers a range of oncology and supportive care products, including Abstral for cancer pain management, Clasteon for bone metastasis-related conditions, Sancuso for chemotherapy-induced nausea, and Oncotype DX for breast cancer recurrence assessment. Additionally, it provides metabolic care products like Gliconorm for diabetes treatment and PYLERA for H. pylori eradication. The company's portfolio further includes CNS care products like Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care products such as Cimzia for rheumatoid arthritis. By addressing critical health issues such as cancer, diabetes, and cardiovascular diseases, NewBridge Pharmaceuticals aims to enhance patient care in its targeted regions.
SuperSonic Imagine
Private Equity Round in 2013
SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.
NewBridge Pharmaceuticals
Series B in 2010
NewBridge Pharmaceuticals Ltd. is a specialty therapeutics company based in Dubai, United Arab Emirates, that focuses on pharmaceuticals, biologics, and medical diagnostics. Established in 2007, the company specializes in in-licensing and commercializing healthcare products to meet the unmet medical needs of patients in the Middle East, Africa, Turkey, and the Caspian regions. NewBridge offers a range of oncology and supportive care products, including Abstral for cancer pain management, Clasteon for bone metastasis-related conditions, Sancuso for chemotherapy-induced nausea, and Oncotype DX for breast cancer recurrence assessment. Additionally, it provides metabolic care products like Gliconorm for diabetes treatment and PYLERA for H. pylori eradication. The company's portfolio further includes CNS care products like Vimpat for seizures and Neupro for Parkinson's disease, as well as immunology care products such as Cimzia for rheumatoid arthritis. By addressing critical health issues such as cancer, diabetes, and cardiovascular diseases, NewBridge Pharmaceuticals aims to enhance patient care in its targeted regions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.